RECRUITINGOBSERVATIONAL
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
About This Trial
This study assesses neurocognitive outcomes after receiving radiation therapy to the brain (whole brain radiation therapy) in patients with blood cancers (hematologic malignancies). This may help researchers learn more about the effects of whole brain radiation therapy on memory and thinking in patients with blood cancer.
Who May Be Eligible (Plain English)
Who May Qualify:
- Age 18 years or older
- Treatment with radiation therapy to the brain for a hematologic malignancy (ex. primary central nervous system lymphoma \[PCNSL\], secondary central nervous system lymphoma \[SCNSL\], leukemia, myeloma)
- Proficient and capable of completing tests in English
- Patients with claustrophobia are eligible if the claustrophobia is managed with medication
- Patients with cognitively-impairment are eligible if the impairment is managed with medication
- Patients who are pregnant
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Age 18 years or older
* Treatment with radiation therapy to the brain for a hematologic malignancy (ex. primary central nervous system lymphoma \[PCNSL\], secondary central nervous system lymphoma \[SCNSL\], leukemia, myeloma)
* Proficient and capable of completing tests in English
* Patients with claustrophobia are eligible if the claustrophobia is managed with medication
* Patients with cognitively-impairment are eligible if the impairment is managed with medication
* Patients who are pregnant
Treatments Being Tested
PROCEDURE
Magnetic Resonance Imaging
Undergo MRI
OTHER
Neurocognitive Assessment
Undergo neurocognitive function assessment
OTHER
Quality-of-Life Assessment
Complete questionnaires
OTHER
Questionnaire Administration
Complete questionnaires
Locations (1)
M D Anderson Cancer Center
Houston, Texas, United States